It has been a crazy couple of week’s for the Share Talk team, we held investors show in London, at The Counting House located right in the heart of the
ValiRx PLC (LON:VAL) Dr Satu Vainikka, CEO Interview
We caught up with Dr Satu Vainikka, CEO of VAL at this year UK Investors Show held in the QE2 building in London.
Share Talk Bulletin Board Heroes, Monday 10th December 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
Share Talk Weekly Stock Market News 17th June 2018
We hope you are having a great weekend, there are plenty of articles to read this week adition. Tekmar Group IPO this week, a market-leading technology provider of protection systems for
ValiRx PLC (AIM:VAL) VAL401 Update
London, UK., 14 June 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide an update on the VAL401 commercial development.
Share Talk Bulletin Board Heroes: 14th June 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers Active Energy(AEG) Canadian Over(COPL) Independent O&G(IOG) Kazera Global(KZG) Live Company(LVCG) Savannah Resources(SAV)
ValiRx Plc (AIM:VAL) ValiSeek Clinical Update (VAL401)
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide an update on the clinical progress and results of VAL401, the anti-cancer compound developed by ValiSeek, the
Valirx Plc (AIM:VAL) US Patent Notice of Allowance for Compound VAL201
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the United States of America patent and trademark office has given notice of allowance for the
Round the Clock Trader TV… How did we do?
Some of our more dedicated readers and listeners will have noted that throughout November and December we worked with Round the Clock Trader Simon Campbell and host Zak Mir alongside
ValiRx Plc (AIM:VAL) VAL201 Clinical trials update
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company has received approval from the MHRA and REC for the Company to expand its
ValiRx Plc (AIM:VAL) ValiSeek Clinical Development Update
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek, the joint
